Loading viewer...
investor_presentation
Format: PDF investor_presentation
Strong 2019 performance Increased mid -term guidance for two core products 20 February 2020UCB Full Year Report 2019
Strong 2019 performance
Increased mid -term guidance
for two core products
20 February 2020UCB Full Year Report 2019
Disclaimer & safe harbor
Forward -looking statements
This presentation contains forward- looking statements, including, without limitation, statements containing the words “believes” , “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”,
“will”, “continue” and similar expressions. These forward- looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts,
are statements that could be deemed forward- looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal,
arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward -looking statements are not guarantees of future performance and are
subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be
materially different from any future results, performance, or achievements expressed or implied by such forward- looking statements contained in this presentation.
Important factors that could result in such differences include but are not limited to: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory
approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under
development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or m anufacturing issues; potential or actual data security and data privacy
breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including
biosimilars, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administ ration of such laws, and hiring and retention of its employees. There is no
guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to
commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in
computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regul atory approval for product marketing has varied in the past and UCB
Preview truncated — download the full document for the complete content.
investor_presentation
16 Pages
Rogers Communications
investor_presentation
CarGurus
investor_presentation
Ternium